Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

IMUGENE LIMITED

INVESTOR PRESENTATION - IMUGENE LIMITED

ASX:IMU

IMUGENE LIMITED

Health Care

Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. The company's product pipeline includes oncolytic viruses (subject to share holders approval at the EGM) and immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Imugene's oncolytic virus known as CF33, is a chimeric vaccinia derived through a recombination of favourable genetic sequences from multiple pox virus strains to generate a new, safer and more potent virus. The PD-1 B-cell vaccine, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies, that have transformed treatment for a range of cancers. PD1-Vaxx has shown encouraging potential in preclinical studies, including outperforming an industry-standard mouse anti-PD-1 antibody in a mouse model of HER2+ colorectal cancer. Imugene also has two HER2 B-cell vaccines in clinical trials, one from Ohio State University (OSU) known as B-Vaxx in Phase 2 clinical trial, and another from the University of Vienna Medical School known as HER-Vaxx in a Phase 1b/2 clinical trial. In earlier Phase I studies, both vaccines showed that they stimulated production of polyclonal antibodies against HER2, with encouraging indications of efficacy, thus providing proof of concept (PoC) for the B-cell vaccine technology as well as suggesting therapeutic potential in HER2+ cancers.

Read more

Market Cap

$493.73m

Price at Close

$0.11

4w avg. Volume

27.99m

4w avg. Turnover

$2.65m

Announcements
announcementt+2 movementdate
  • Appendix 2A

    Issued Capital

  • -

    24 Nov 2020

-

24 Nov 2020
  • Proposed issue of Securities - IMU

    Issued Capital

  • -

    24 Nov 2020

-

24 Nov 2020
  • Results of Meeting

    Notice Of Meeting

  • -

    24 Nov 2020

-

24 Nov 2020
  • Investor Presentation

    Periodic Reports

  • -4.35%

    23 Nov 2020

-4.35%

23 Nov 2020
  • AGM Presentation

    Periodic Reports

  • -4.35%

    23 Nov 2020

-4.35%

23 Nov 2020
  • Imugene HER Vaxx shows positive Overall Survival in trial

    Progress Report · Market sensitive

  • -4.35%

    22 Nov 2020

-4.35%

22 Nov 2020
  • Release of Securities from Escrow

    Issued Capital

  • +2.04%

    18 Nov 2020

+2.04%

18 Nov 2020
  • Appendix 2A

    Issued Capital

  • -8.00%

    17 Nov 2020

-8.00%

17 Nov 2020
  • Proposed issue of Securities - IMU

    Issued Capital

  • -8.00%

    17 Nov 2020

-8.00%

17 Nov 2020
  • Proposed issue of Securities - IMU

    Issued Capital

  • +27.42%

    10 Nov 2020

+27.42%

10 Nov 2020
Market Data

Current Price

$0.11

52WK HIGH

$0.14

52WK LOW

$0.016

1YR RETURN

+120.00%

1YR RETURN VS. SECTOR

+101.20%

90 DAY RETURN

+89.66%

ASX RANK

381

/2,024

SECTOR RANK

8

/47

SHARES OUTSTANDING

4.49b
ASX:IMU

IMUGENE LIMITED

Health Care

Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. The company's product pipeline includes oncolytic viruses (subject to share holders approval at the EGM) and immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Imugene's oncolytic virus known as CF33, is a chimeric vaccinia derived through a recombination of favourable genetic sequences from multiple pox virus strains to generate a new, safer and more potent virus. The PD-1 B-cell vaccine, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies, that have transformed treatment for a range of cancers. PD1-Vaxx has shown encouraging potential in preclinical studies, including outperforming an industry-standard mouse anti-PD-1 antibody in a mouse model of HER2+ colorectal cancer. Imugene also has two HER2 B-cell vaccines in clinical trials, one from Ohio State University (OSU) known as B-Vaxx in Phase 2 clinical trial, and another from the University of Vienna Medical School known as HER-Vaxx in a Phase 1b/2 clinical trial. In earlier Phase I studies, both vaccines showed that they stimulated production of polyclonal antibodies against HER2, with encouraging indications of efficacy, thus providing proof of concept (PoC) for the B-cell vaccine technology as well as suggesting therapeutic potential in HER2+ cancers.

Read more

Market Cap

$493.73m

Price at Close

$0.11

4w avg. Volume

27.99m

4w avg. Turnover

$2.65m

ASX:IMU is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.